Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REPL Replimune Group Inc.

Not Yet Opened 05-04 16:00:00 EDT

3.03

+0.53

+21.20%

盘后2.96

-0.07-2.31%

19:56 EDT

High3.14	Low2.55	Vol6.78M
Open2.55	D1 Closing2.50	Amplitude23.60%
Mkt Cap250.19M	Tradable Cap151.40M	Total Shares82.57M
T/O20.14M	T/O Rate13.57%	Tradable Shares49.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":3.03,"timestamp":1777924800000,"preClose":2.5,"halted":0,"volume":6778575,"hourTrading":{"tag":"盘后","latestPrice":2.96,"preClose":3.03,"latestTime":"19:56 EDT","volume":58045,"amount":175681.2446,"timestamp":1777938973955,"change":-0.07,"changeRate":-0.023102,"amplitude":0.049505},"delay":0,"changeRate":0.2119999999999999,"floatShares":49968589,"shares":82572600,"eps":-3.435956,"marketStatus":"Not Yet Opened","change":0.53,"latestTime":"05-04 16:00:00 EDT","open":2.55,"high":3.14,"low":2.55,"amount":20144902.69089,"amplitude":0.236,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.435956,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777968000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":2.5,"preHourTrading":{"tag":"盘前","latestPrice":2.56,"preClose":2.5,"latestTime":"09:29 EDT","volume":39924,"amount":102026.7920772,"timestamp":1777901399999,"change":0.06,"changeRate":0.024,"amplitude":0.05328},"postHourTrading":{"tag":"盘后","latestPrice":2.96,"preClose":3.03,"latestTime":"19:56 EDT","volume":58045,"amount":175681.2446,"timestamp":1777938973955,"change":-0.07,"changeRate":-0.023102,"amplitude":0.049505},"volumeRatio":1.627449,"optionData":{"bulkOrders":[{"symbol":"REPL","call":false,"expireDate":1778817600000,"strike":"3.0","timestamp":1777917324471,"price":0.25,"volume":1500,"amount":37500,"type":"-"}]},"impliedVol":1.494,"impliedVolPercentile":0.7331},"requestUrl":"/m/hq/s/REPL","defaultTab":"news","newsList":[{"id":"2630396748","title":"Replimune to present IGNYTE trial survival data at ASCO annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396748?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:09","pubTimestamp":1777291764,"startTime":"0","endTime":"0","summary":"Replimune will present clinical data at 2026 ASCO Annual Meeting in Chicago, May 29 to June 2, 2026.Oral presentation on 3-year landmark overall survival from IGNYTE trial of RP1 with nivolumab in anti-PD-1-failed melanoma scheduled for May 30, 2026.Second oral presentation on final Phase 1 safety, efficacy, biomarker results for RP2 alone or with nivolumab in advanced solid tumors scheduled for May 31, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL5m5kG8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014013.SGD","NDAQ","LU2095319765.USD","BK4139","SG9999014005.SGD","BK4588","SG9999014021.USD","IE00BN0W2W23.USD","BK4112","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","REPL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396161","title":"Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396161","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396161?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:00","pubTimestamp":1777291200,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., April  27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ann","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281576/0/en/Replimune-to-Present-at-the-2026-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","HCC","BK4107","BK4006","AFG","BTC","BK4117","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629902608","title":"US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection","url":"https://stock-news.laohu8.com/highlight/detail?id=2629902608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629902608?lang=en_us&edition=fundamental","pubTime":"2026-04-23 00:54","pubTimestamp":1776876887,"startTime":"0","endTime":"0","summary":"US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejectionKennedy says FDA Commissioner Makary made decision not to approve drugWSJ opinion piece calls for Makary to be replacedReplimune shares gain 15%By Ahmed Aboulenein and Puyaan Singh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL1N4150U0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629435028","title":"Replimune rises after Wall Street Journal editorial defending RP1","url":"https://stock-news.laohu8.com/highlight/detail?id=2629435028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629435028?lang=en_us&edition=fundamental","pubTime":"2026-04-22 23:00","pubTimestamp":1776870052,"startTime":"0","endTime":"0","summary":"In an opinion article, The Wall Street Journal’s The Editorial Board argued that the Food and Drug Administration’s rejection of Replimune’s (REPL)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-rises-after-wall-street-journal-editorial-defending-rp1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-rises-after-wall-street-journal-editorial-defending-rp1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627425134","title":"Replimune Group (REPL) was downgraded to a Hold Rating at Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2627425134","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627425134?lang=en_us&edition=fundamental","pubTime":"2026-04-15 01:15","pubTimestamp":1776186920,"startTime":"0","endTime":"0","summary":"Replimune Group received a Hold rating and a $2.00 price target from Leerink Partners analyst Jonathan Chang yesterday. According to TipRanks, Chan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/replimune-group-repl-was-downgraded-to-a-hold-rating-at-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/replimune-group-repl-was-downgraded-to-a-hold-rating-at-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627813469","title":"NASD Most Active Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=2627813469","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627813469?lang=en_us&edition=fundamental","pubTime":"2026-04-14 05:41","pubTimestamp":1776116460,"startTime":"0","endTime":"0","summary":"Direxion TSLA Bull 2X       TSLL    92,550,871     10.81     0.20      1.89. Leverage 2X Lg BMNR Dly     BMNG    74,142,273      1.41     0.03      2.17. Leverage 2X Lg TSLA Dly     TSLG    71,932,545      5.32     0.09      1.72. Direxion PLTR Bear 1X       PLTD    71,194,195      8.24    -0.27     -3.17. ProShares UltraPro QQQ      TQQQ    65,583,129     50.66     1.49      3.03. GrShr 2x Sh NVDA Daily       NVD    64,082,272      6.40    -0.04     -0.62. Leverage 2X Lg CRWV Dly     CRWG    57,493,260      4.68     0.66     16.42. CoreWeave Cl A              CRWV    55,683,178    110.27     8.27      8.11. ProSh UltraPro Shrt QQQ     SQQQ    48,050,544     65.57    -2.05     -3.03. American Airlines Group      AAL    43,826,308     11.23    -0.09     -0.80","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2860962120.EUR","LU1983260115.SGD","LU2125154935.USD","LU1868836914.USD","NVDW","LU0109392836.USD","BK4532","LU2054465674.USD","LU0528227936.USD","LU0444973449.USD","LU2125909593.SGD",".IXIC","LU2242649171.HKD","LU0557290698.USD","LU1989764664.SGD","LU2272731865.HKD","IE000YTNTUN2.SGD","LU1868837136.USD","LU1127390331.HKD","SG9999002679.SGD","LU2065171311.SGD","LU0210536198.USD","SG9999002620.SGD","LU1066051811.HKD","LU1366333091.USD","LU0345768153.USD","NVDG","LU0823411888.USD","IE00BQXX3C00.GBP","LU2271345857.HKD","LU1623119135.USD","LU1645745479.HKD","LU2487616109.SGD","LU2322448957.HKD","BK4022","LU1935043023.USD","LU0348723411.USD","LU2083900584.USD","LU2242650005.HKD","LU0109391861.USD","SGXZ51526630.SGD","NVDY","LU0672654240.SGD","LU1803068979.SGD","HK0000320264.USD","IE0004086264.USD","LU0823421333.USD","LU1244550494.USD","BK4605","LU2294711713.HKD","PLTG","IE000KEQY171.SGD","TESL","LU2286300806.USD","IE00BWXC8680.SGD","LU1674673428.USD","LU0072462426.USD","GRAB","LU0267386448.USD","LU0175139822.USD","IE00BJLML261.HKD","LU1119994496.HKD","NVD2.UK","LU0788109477.HKD","LU0128525929.USD","LU1316542783.SGD","LU2106854487.HKD","SGXZ58947870.SGD","LU1280957306.USD","CRWV","LU0154236417.USD","LU2023250330.USD","SG9999001135.SGD","LU0342679015.USD","LU2756315318.SGD","TSLZ","ALLO","LU0985320562.USD","LU2023251221.USD","LU2125909916.SGD","LU2430703095.HKD","HK0000819398.USD","IE0004091025.USD","HK0000306685.HKD","LU1548497426.USD","SG9999002406.SGD","IE00B4YYXB79.USD","LU0354030438.USD","LU2417539215.USD","TSLG","LU1791710400.SGD","LU2360107168.USD","BK4575","LU1712237335.SGD","3NVD.UK","LU2471134952.CNY","LU0053666078.USD","SOFI","CORD","LU1791710582.SGD","LU1400636491.USD","LU0347712357.USD","LU1923623000.USD","IE00BN29S564.USD","NVDX","NVIW.SI","LU0106261372.USD","LU0823414478.USD","LU2462157665.USD","LU0354030511.USD","LU2092937148.SGD","LU2505996681.GBP","IE00BKDWB100.SGD","HK0000532082.HKD","IE0004445015.USD","LU1989764748.USD","INTW","HK0000306701.USD","BK4527","IE0004445239.USD","HK0000320223.HKD","IE00BMPRXR70.SGD","LU0107464264.USD","SGXZ99366536.SGD","LU1064131342.USD","LU0289961442.SGD","LU2552382132.HKD","LU1035775433.USD","PLOO","LINT","LU2247934214.USD","LU0689626769.HKD","LU1914381329.SGD","LU2097344431.USD","LU2237957811.SGD","BK4122","LU2592432038.USD","LU0289739343.SGD","LU0096364046.USD","IE00B19Z9P08.USD","IE00BJTD4N35.SGD","LU2360032135.SGD","NVD","LU2430703251.USD","SG9999002224.SGD","REPL","LU1778281490.HKD","LU0308772762.SGD","LU1691799644.USD","HK0000914686.HKD","LU1852331112.SGD","LU0266013472.USD","SG9999000418.SGD","SG9999013460.SGD","LU0203201768.USD","SG9999013486.USD","IE00BK4W5L77.USD","LU1718418525.SGD","SG9999014575.USD","BK4516","NVDQ","LU0683600562.USD","LU2463028550.USD","IE000W1ABFV2.USD","IE00B1BXHZ80.USD","LU0444971666.USD","LU1935042991.SGD","LU1988902786.USD","TSLW","LU1037948541.HKD","LU2357125470.USD","LU2456880835.USD","LU0511384066.AUD","LU0868494708.USD","LU1244550221.USD","LU0466842654.USD","LU0820561909.HKD","LU0323591593.USD","LU1069344957.HKD","LU2045819591.USD","LU1814569148.SGD","LU2168564495.EUR","LU2491050071.SGD","LU0187121727.USD","LU2272731600.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","SG9999018865.SGD","IE00BFSS8Q28.SGD","BK4008","LU1861220033.SGD","CWVX","LU0170899867.USD","LU2125909759.SGD","AMZN","NVDO","LU1366192091.USD","SG9999017495.SGD","LU1934455194.USD","SG9999014906.USD","LU2077746001.SGD","LU2065170008.USD","LU0210637038.USD","LU1429558221.USD","BK4543","LU1145028129.USD","LU0942090050.USD","LU1670756490.USD","LU0494093205.USD","LU0345769631.USD","LU1435385759.SGD","IE00BZ9MQY76.HKD","LU0787776722.HKD","LU2362541513.USD","SGXZ81514606.USD","LU0965509101.SGD","LU2471134523.USD","LU0353189763.USD","LU2746668974.SGD","BK4548","LU1720051108.HKD","IE00BK4W5M84.HKD","SG9999004303.SGD","LU2491049909.HKD","TSLQ","NVD3.UK","BYND","LU2357305700.SGD","IE0009356076.USD","LU1935042215.USD","LU1084165304.USD","TSLP","LU0157215616.USD","LU0823421416.USD","LU2063271972.USD","BK4608","LU2108987350.USD","TQQQ","TSII","IE00B775SV38.USD","LU2191332357.HKD","LU0708994859.HKD","LU2505996509.AUD","AALG","LU1267930730.SGD","LU0868494617.USD","LU0889565833.HKD","LU2023250504.SGD","NDX","IE00B1XK9C88.USD","LU2265009873.SGD","LU0079474960.USD","NVDS","LU0823434740.USD","LU1153585028.USD","SG9999014898.SGD","LU1699723380.USD","BK4592","LU2111349929.HKD","LU1935043536.SGD","IE0034235303.USD","LU0823414551.USD","HK0000304805.HKD","LU2461242641.AUD","LU0724617625.USD","LU1951200564.SGD","CRSH","NVDA","TSLS","AAL","SG9999015978.USD","TSLA","IE0005OL40V9.USD","BK4529","LU0238689110.USD","LU0321505439.SGD","LU2125154778.USD","LU0203202063.USD","LU1861558580.USD","LU2458330169.SGD","BK4587","IE00BYXW3230.USD","SG9999015341.SGD","LU1232071149.USD","SG9999002604.SGD","IE0034235188.USD","LU2249611893.SGD","LU0234570918.USD","TSLY","IE00B19Z9Z06.USD","LU0225283273.USD","LU1066051498.USD","BK4604","LU0640476718.USD","PLTI","LU1934455277.USD","CRWG","LU0708995401.HKD","SG9999014559.SGD","LU2361044865.SGD","LU0964807845.USD","LU1861215975.USD","LU2168563687.JPY","LU2746668461.USD","BK4602","LU1989772840.SGD","BK4612","SG9999013478.USD","04335","PTIR","IE00BMPRXQ63.HKD","SG9999015986.USD","LU1066053197.SGD","LU1815333072.USD","LU0081259029.USD","LU2471134879.HKD","IE00BD6J9T35.USD","IE00BJJMRX11.SGD","BK4585","HK0000304797.USD","LU2290526834.HKD","LU1923622614.USD","SG9999018857.SGD","IE0001KFT4U8.USD","IE00BQXX3D17.EUR","LU1037948897.HKD","TSLR","SG9999014914.USD","LU0472753341.HKD","SG9999014880.SGD","BK4511","LU0965509010.AUD","LU0345768740.USD","SG9999002414.USD","LU1633808545.USD","LU2413666426.HKD","LU2452424414.USD","LU2750360997.AUD","DIPS","IE00B4JS1V06.HKD","LU2065169927.USD","LU2087625088.SGD","LU0158827781.USD","LU0057025933.USD","LU2473716301.USD","LU0061474960.USD","PLYY","BK4574","LU2028103732.USD","SG9999001424.SGD","LU1868836757.USD","IE00B7KXQ091.USD","SG9999015952.SGD","BK4515","LU0823434583.USD","LU0719512351.SGD","LU1861127337.USD","BK4500","LU2360106780.USD","BK4230","PLTR","SG9999014567.USD","LU1989772923.USD","LU1868837300.USD","BK4141","LU2213496289.HKD","IE00BSNM7G36.USD","LU1242518931.SGD","BK4555","IE0034235295.USD","LU0124676726.USD","LU1629891620.HKD","IE00BZ199S13.USD","TSDD","BMNG","NVDS.UK","LU1202635105.USD","LU1244550577.SGD","BK4503","LU2931357623.SGD","PLTY","NVDU","LU2403377893.USD","LU0011850046.USD","LU2089284900.SGD","BK4535","LU0070217475.USD","SG9999002232.USD","LU1674673691.USD","LU1267930573.SGD","PLTZ","LU2065171402.SGD","LU2413666699.HKD","LU0077335932.USD","LU2506951792.HKD","LU0345770993.USD","LU2322448791.USD","LU2148611432.USD","IE00B894F039.SGD","LU0310800379.SGD","LU0532188223.SGD","LU1496350502.SGD","LU0069063385.USD","LU2250418816.HKD","LU2361045086.USD","LU2756315664.SGD","IE000M9KFDE8.USD","IE00BQXX3F31.USD","LU0957791311.USD","IE0003U64NQ7.SGD","LU2896262040.SGD","LU0082616367.USD","SGXZ31699556.SGD","LU1267930490.SGD","BK4567","TSLO","LU0210528500.USD","LU0965508806.USD","LU2092627202.USD","TSL","2NVD.UK","BK4588","LU0048584097.USD","LU1992135472.HKD","LU2125909247.SGD","TSLI","IE00B19Z8X17.USD","LU0345770308.USD","LU0786609619.USD","LU2089283258.USD","BK4550","IE00BJTD4V19.USD","GB00BDT5M118.USD","BK4598","BK4614","BMNR","IE000ITXATA3.USD","CRWU","BK4099","TLA","LU0310799852.SGD","LU0276348264.USD","LU0943347566.SGD","BK4613","LU2602419157.SGD","HK0000914660.USD","LU0320765059.SGD","LU0198837287.USD","LU0251132253.USD","LU0265550946.USD","NVDD","LU0061474705.USD","LU2552382058.USD","LU0820561818.USD","LU2237957902.USD","LU1974910355.USD","IE00BDRTCR15.USD","LU0345769128.USD","BK4512","LU1323610961.USD","IE00B5949003.HKD","LU0080751232.USD","SGXZ23171101.USD","BK4581","LU1400636657.SGD","IE00B19Z9505.USD","LU1116320901.HKD","LU2168564065.EUR","LU1804176565.USD","PLT","LU0316494557.USD","LU0210533765.USD","SG9999006266.SGD","LU2244417387.USD","IE00BHPRN162.USD","PLTU","IE00BDCRKT87.USD","INTC","LU0820562030.AUD","LU1400636574.HKD","IE00B775H168.HKD","LU0056508442.USD","LU1923622291.USD","NVDB","LU2458330243.SGD","LU2361044949.HKD","LU1721428933.USD","LU1917777945.USD","LU2087621335.USD","LU0256863811.USD","LU0097036916.USD","SG9999015358.SGD","BK4579","PLTD","LU0353189680.USD","IE00BMPRXN33.USD","SG9999015945.SGD","PLTW","LU2430703178.SGD","LU0215105999.USD","LU2089985449.USD","PLTA","LU0127658192.USD","LU0211328371.USD","LU0689472784.USD","LU2750360641.GBP","LU1951198990.SGD","SNVD.UK","BK4551","TSYY","BK4116","LU0006306889.USD","LU2491050154.USD","NVII","LU2362541273.HKD","SG9999014542.SGD","LU2420271590.USD","IE0009G5SDU7.USD","LU1720051017.SGD","LU1551013425.SGD","IE00BKPKM429.USD","LU1992135399.USD","LU0417517546.SGD","LU0965509283.SGD","IE00B3S45H60.SGD","LU1934455863.HKD","BK4023","BK4547","IE00B3SWFQ91.USD","LU2543165471.USD","ANV","LU2362540622.SGD","LU2168564149.EUR","LU2552382215.SGD","LU0957808578.USD","BK4534","BK4549","LU1116320737.USD","LU1261432733.SGD","LU1642822529.SGD","07766","NVDL","LU2237438978.USD","IE00BFSS7M15.SGD","LU0274383776.USD","LU2211815571.USD","LU0979878070.USD","LU2236285917.USD","LU0158827948.USD","LU1821325948.USD","IE00BKVL7J92.USD","LU2264538146.SGD","TSLL","BK4554","LU0321505868.SGD","LU0265550359.USD","LU0289960550.SGD","LU0211327993.USD","LU2097344357.USD","LU1496350171.SGD","LU2272731782.SGD","LU0234572021.USD","BK4533","LU2433249047.HKD","SQQQ","IE00B19Z8W00.USD","IE00B3M56506.USD","LU0390134368.USD","LU1066051225.USD","LU1839390173.USD","LU2381873111.SGD","LU0476273544.USD","LU0096362180.USD","LU0882574139.USD","IE00BJJMRY28.SGD","LU2326559502.SGD","LU1242518857.USD","LU0094547139.USD","LU1551013342.USD","LU0861579265.USD","LU0642271901.SGD","LU0441851309.USD","LU2168564222.USD","LU1861559042.SGD","LU1815336760.USD","LU1935042488.USD","LU2471134796.USD","LU0061475181.USD","LU0256863902.USD","LU1839511570.USD","LU1868836591.USD","LU2125910500.SGD","TEST","TSLT","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627450630","title":"BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune","url":"https://stock-news.laohu8.com/highlight/detail?id=2627450630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627450630?lang=en_us&edition=fundamental","pubTime":"2026-04-14 01:50","pubTimestamp":1776102619,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, ReplimuneWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL6N40W0LU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DOW","LYB","NOW","CRM","GOOGL","OXY","XOM","DVN","HP","TFX","GPRO","APTV","MARA","LEG","HUT","CVX","SNDK","BIIB","META","CAG","SBUX","OCUL","ALLO","KYMR","DAL","DIOD","ADBE","NEM","SYRE","LUV","UAL","APP","HPE","COIN","GFL","IBM","IMA","AVT","IDYA","CDE","ANIP","ORCL","PINS","HL","EMN","REPL","RVMD","BBY","RIOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627506734","title":"FDA Rejection Sparks Questions On Replimune Drug Approval Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2627506734","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627506734?lang=en_us&edition=fundamental","pubTime":"2026-04-14 01:44","pubTimestamp":1776102240,"startTime":"0","endTime":"0","summary":"Replimune gets FDA CRL for RP1 melanoma therapy, disputes review process as analysts cut ratings and price targets sharply.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/13/Motala--Sweden--7-January-2023-Fda-Logo-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/13/Motala--Sweden--7-January-2023-Fda-Logo-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/downgrades/26/04/51788005/fda-rejection-sparks-questions-on-replimune-drug-approval-path","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/downgrades/26/04/51788005/fda-rejection-sparks-questions-on-replimune-drug-approval-path","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4530","BK4588","BK4139","LABU","LU0390134368.USD","LU0757428866.USD","BK4585","LU0128526141.USD","LU1815336091.USD","BK4121","CRL","IE00BFMHRM44.USD","REPL","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627547694","title":"Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2627547694","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627547694?lang=en_us&edition=fundamental","pubTime":"2026-04-13 23:52","pubTimestamp":1776095520,"startTime":"0","endTime":"0","summary":"Shares of Replimune Group continued their downward spiral on Monday after the biotechnology company cautioned that it was facing mass layoffs and cutbacks in its manufacturing operations after regulators twice rejected an application for an experimental cancer therapy.The stock ended Friday's session down more than 19% at $4.76, its lowest level since mid-October. Replimune cratered another 64% on Monday to $1.68, on pace for a record closing low.The selloff began after the Food and Drug Administration declined to approve Replimune's immunotherapy candidate, RP1, in combination with Bristol Myers Squibb's Opdivo for the treatment of advanced melanoma.In a letter viewed by Barron's, regulators echoed concerns from a prior communication with the biotechnology company, largely pertaining to the study design and lack of \"evidence of effectiveness.\". \"The country's foremost melanoma specialists stood behind the RP1 data,\" Patel said. \"Patients and caregivers pleaded for urgency. All of it w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1261432733.SGD","BK4585","LU1074936037.SGD","LU1868836591.USD","LU2360032135.SGD","LU1323610961.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","LU0306807586.USD","LABU","LU0306806265.USD","LU0321505868.SGD","LU0985481810.HKD","LU2133065610.SGD","LU1670711123.USD","LU0882574055.USD","IE00B2B36J28.USD","LU1983299246.USD","LU1430594728.SGD","LU0225771236.USD","LU1585245621.USD","BMY","LU1093756168.USD","LU1883839398.USD","BK4559","LU1670710661.SGD","LU0114720955.EUR","LU1032466523.USD","IE0002141913.USD","LU1868836914.USD","BK4534","LU0456855351.SGD","BK4139","REPL","LU1670711040.USD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU2242646821.SGD","LU0096364046.USD","LU0237698245.USD","LU0061475181.USD","BK4532","LU2242652126.USD","LU0225284248.USD","LU1718418525.SGD","LU0868494617.USD","BK4581","LU1670710588.SGD","LU1868836757.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627144454","title":"BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627144454","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627144454?lang=en_us&edition=fundamental","pubTime":"2026-04-13 23:43","pubTimestamp":1776095026,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-SonomaWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL6N40W0Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBM","CRWV","DOW","HL","SNDK","MARA","PINS","DAL","LEG","ALLO","LYB","AAL","TFX","SBUX","META","REPL","OXY","BIIB","HTFL","NEM","EMN","OCUL","IDYA","ADBE","SBU","GOOGL","AVT","BBY","XOM","WSM","GPRO","UAL","CAG","HPE","DVN","OWL","DIOD","RVMD","HUT","ANIP","CDE","RIOT","LUV","IMA","SYRE","CVX","COIN","APTV","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627454690","title":"Replimune Group Facing 'Significant Risk' on RP1's Ongoing Phase 3 Study, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2627454690","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627454690?lang=en_us&edition=fundamental","pubTime":"2026-04-13 23:30","pubTimestamp":1776094237,"startTime":"0","endTime":"0","summary":"Replimune Group  is facing \"significant risk\" related to the ongoing phase 3 study of RP1 in melanoma after the US Food and Drug Administration rejected the company's biologics license application for the product candidate, Wedbush Securities said in a Monday note.The FDA rejected the application, citing response assessment uncertainty, study population heterogeneity, and failure to isolate RP1's contribution when administered in combination with nivolumab as deficiencies in the phase 2 IGNYTE trial of of RP1, the brokerage noted.\"We see no path forward for RP1 with IGNYTE,\" Wedbush said.Wedbush downgraded its rating on Replimune Group to neutral from outperform, with a lower price target of $2 from $19.Shares of Replimune Group were down more than 62% around midday Monday.Price: 1.81, Change: -2.95, Percent Change: -62.02","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627545094","title":"Replimune Shares Plummet to All-Time Low as FDA Rejection Muddies Path Forward","url":"https://stock-news.laohu8.com/highlight/detail?id=2627545094","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627545094?lang=en_us&edition=fundamental","pubTime":"2026-04-13 23:29","pubTimestamp":1776094140,"startTime":"0","endTime":"0","summary":"Shares of Replimune Group continued their free fall and touched an all-time low after the company's application for a melanoma treatment was rejected by the Food and Drug Administration for a second time, which analysts said raises considerable uncertainty for the company's path forward.Shares were down 61% to $1.86 in Monday morning trading, after hitting their all-time low of $1.50 earlier in the session. The stock has now fallen about 75% this year.The FDA on Friday said the biotechnology company failed to provide data showing that RP1, also known as vusolimogene oderparepvec, can effectively treat unresectable advanced cutaneous melanoma. Replimune fired back at the FDA later Friday, accusing the agency of inconsistencies and poor communication.\"We see no path forward for RP1 with Ignyte, and significant risk with regards to the ongoing Ph 3 study,\" Wedbush analysts wrote in a note, downgrading the stock to neutral and cutting their price target to $2 from $19.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABU","REPL","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627451661","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:52 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2627451661","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627451661?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:52","pubTimestamp":1776091971,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:52 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nAQN2LUF3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627344459","title":"Replimune Group Cut to Neutral From Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2627344459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627344459?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:04","pubTimestamp":1776089040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REPL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 13, 2026 10:04 ET (14:04 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627456875","title":"Replimune Shares Decline 66.3% as at Least Six Brokerages Downgrade Stock After Co's Drug Fails to Win FDA Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2627456875","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627456875?lang=en_us&edition=fundamental","pubTime":"2026-04-13 21:32","pubTimestamp":1776087131,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL4N40W12X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627584914","title":"BUZZ-Street View: Tough path ahead for Replimune after second FDA setback on melanoma drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2627584914","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627584914?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:21","pubTimestamp":1776082917,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Tough path ahead for Replimune after second FDA setback on melanoma drug    ** Shares of Replimune REPL.O fall 63.66% to $1.73 premarket** U.S. Food and Drug Administration on Friday declined to approve Replimune's drug for advanced skin cancer, citing insufficient data from studies** At least three analysts cut PT on company COMPANY IN SIGNIFICANT CRISIS** Wedbush  says second complete response letter is \"disappointing\" given what brokerage views as convincing treatment effect in patient population with significant unmet need** BMO Capital Markets  says company is left with long and financially challenging path forward** J.P. Morgan  anticipates company will likely need to restructure and deprioritize earlier stage pipeline efforts** H.C. Wainwright  says it may take REPL until late in this decade to furnish agency with data that it appears to be demanding, downgrading to stock to sell without price target** Adds there can be no assurance that Replimune would be able","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL4N40W0UB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627303124","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2627303124","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627303124?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:47","pubTimestamp":1776080858,"startTime":"0","endTime":"0","summary":"Replimune Group  shares were down nearly 64% in premarket activity Monday. On Friday, the US Food and Drug Administration said it rejected the company's biologics license application for vusolimogene oderparepvec. Also, multiple analysts downgraded their ratings on Replimune's stock.Strive Asset Management  stock was down 4.7% pre-bell, paring Friday's rally.Best Buy  stock was 4.5% lower after Goldman Sachs downgraded the company to sell from buy and lowered its price target to $59 from $76.Petco Health & Wellness  shares were down 2.5% after Goldman Sachs downgraded the company to neutral from buy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASST","LU0251142724.SGD","LU0868494617.USD","BK4009","BK4127","GSX","BBY","LU1868836914.USD","LU2237443465.HKD","LU2237443895.HKD","LU2471134879.HKD","BK4588","LU1868837300.USD","LU0345770993.USD","LU2750360997.AUD","LU2237443622.USD","LU2237443382.USD","LU2750360641.GBP","LU2237443549.SGD","BK4082","BK4139","LU1868837136.USD","IE0002270589.USD","LU1804176565.USD","IE0004091025.USD","LU0251131958.USD","LU0345770308.USD","LU0742534661.SGD","LU0942090050.USD","LU0061475181.USD","BK4552","IE0004086264.USD","LU2237443978.SGD","IE00BFXG1179.USD","LU0048573561.USD","BK4076","LU1868836757.USD","IE00B19Z3581.USD","LU1868836591.USD","LU2471134523.USD","BK4504","LU2471134952.CNY","BK4585","BK4200","LU2471134796.USD","IE0034235188.USD","IE00BSNM7G36.USD","LU0106831901.USD","BK4135","BK4516","LU0868494708.USD","IE00B19Z3B42.SGD","BK4567","REPL","BK4533","WOOF","LU2237438978.USD","GS","LU1791807156.HKD","LU1894683264.USD","LU1668664300.SGD","BK4550","GSCE","LU2265009873.SGD","LU1894683348.USD","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627323874","title":"Replimune Group Inc : Bmo Cuts to Underperform From Market Perform; Cuts Target Price to $1 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2627323874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627323874?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:58","pubTimestamp":1776077907,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40W0MS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627807432","title":"Wedbush Downgrades Replimune Group to Neutral From Outperform, Cuts Price Target to $2 From $19","url":"https://stock-news.laohu8.com/highlight/detail?id=2627807432","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627807432?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:57","pubTimestamp":1776077837,"startTime":"0","endTime":"0","summary":"Replimune Group (REPL) has an average rating of hold and mean price target of $7.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627434942","title":"Replimune Group Cut to Sell From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2627434942","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627434942?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:39","pubTimestamp":1776076740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REPL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 13, 2026 06:39 ET (10:39 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com","stockEarnings":[{"period":"1week","weight":0.0331},{"period":"1month","weight":-0.6715},{"period":"3month","weight":-0.6444},{"period":"6month","weight":-0.7431},{"period":"1year","weight":-0.7407},{"period":"ytd","weight":-0.7428}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.050762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.088086},{"month":4,"riseRate":0.5,"avgChangeRate":0.020849},{"month":5,"riseRate":0.375,"avgChangeRate":-0.046026},{"month":6,"riseRate":0.857143,"avgChangeRate":0.223071},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.088436},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}